These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7451364)

  • 21. [In vitro evaluation of antibacterial activity of the original oxime type of beta-lactam antibiotics with the 4-aminobenzensulfonamide group].
    Holá V; Adensamová J; Mandel M
    Cesk Farm; 1990 Sep; 39(7):299-301. PubMed ID: 2098201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
    Kim C; Hesek D; Lee M; Mobashery S
    Bioorg Med Chem Lett; 2018 Feb; 28(4):642-645. PubMed ID: 29402738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Susceptibilities of uropathogenic bacteria to ampicillin, cefazolin, cefmetazole and gentamicin. Nine-year survey of changing patterns of susceptibilities].
    Igari J; Shitara M; Shitara M; Yoshimoto K; Hayashi Y
    Jpn J Antibiot; 1990 Sep; 43(9):1530-7. PubMed ID: 2262960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of ceftriaxone against clinical bacterial isolates in Nigeria.
    Obaseiki-Ebor EE; Afonya TC; Oyaide SM
    Chemotherapy; 1985; 31(2):130-7. PubMed ID: 3872779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial compounds of Canadian honeys target bacterial cell wall inducing phenotype changes, growth inhibition and cell lysis that resemble action of β-lactam antibiotics.
    Brudzynski K; Sjaarda C
    PLoS One; 2014; 9(9):e106967. PubMed ID: 25191847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of blood isolates to various antibiotics, in particular to cephalosporins.
    Ling J; Chau PY; Leung YK; Ng WS
    J Antimicrob Chemother; 1983 May; 11(5):473-80. PubMed ID: 6874632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics.
    Tan CM; Therien AG; Lu J; Lee SH; Caron A; Gill CJ; Lebeau-Jacob C; Benton-Perdomo L; Monteiro JM; Pereira PM; Elsen NL; Wu J; Deschamps K; Petcu M; Wong S; Daigneault E; Kramer S; Liang L; Maxwell E; Claveau D; Vaillancourt J; Skorey K; Tam J; Wang H; Meredith TC; Sillaots S; Wang-Jarantow L; Ramtohul Y; Langlois E; Landry F; Reid JC; Parthasarathy G; Sharma S; Baryshnikova A; Lumb KJ; Pinho MG; Soisson SM; Roemer T
    Sci Transl Med; 2012 Mar; 4(126):126ra35. PubMed ID: 22440737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of imipenem on aerobic bacteria.
    Acar JF; Goldstein FW; Kitzis MD; Gutmann L
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():37-45. PubMed ID: 6421793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics.
    Song KH; Jung SI; Lee S; Park S; Kim ES; Park KH; Park WB; Choe PG; Kim YK; Kwak YG; Kim YS; Jang HC; Kiem S; Kim HI; Kim HB;
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):67-74. PubMed ID: 30269181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PS-5, a new beta-lactam antibiotic. III. Synergistic effects and inhibitory activity against a beta-lactamase.
    Okamura K; Sakamoto M; Fukagawa Y; Ishikura T; Lein J
    J Antibiot (Tokyo); 1979 Apr; 32(4):280-6. PubMed ID: 381269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of antimicrobial activity of beta-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan.
    Ishii Y; Alba J; Kimura S; Shiroto K; Yamaguchi K
    Int J Antimicrob Agents; 2005 Apr; 25(4):296-301. PubMed ID: 15784308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nocardicin A, a new monocyclic beta-lactam antibiotic III. In vitro evaluation.
    Nishida M; Mine Y; Nonoyama S; Kojo H
    J Antibiot (Tokyo); 1977 Nov; 30(11):917-25. PubMed ID: 412823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].
    Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Uehara N; Yasujima M; Kasai T; Suwabe A; Yamahata K; Kaku M; Kanemitsu K; Imafuku Y; Nishiyama K; Murakami M; Yomoda S; Taniguchi N; Yamada T; Nomura F; Watanabe M; Kanno H; Aihara M; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Yamazaki F; Horii T; Maekawa M; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Iinuma Y; Maeda S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kinoshita S; Fujita J; Negayama K; Murase M; Miyamoto H; Kusano N; Mihara E; Itaha H; Ono J; Yoshimura H; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
    Jpn J Antibiot; 2007 Dec; 60(6):344-77. PubMed ID: 18447206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.